Market Overview

Shares of Intercept Pharma Rise as BofA Sees US, EU Regulators Giving A Thumbs Up

Related ICPT
Mid-Morning Market Update: Markets Open Lower; Carlyle Group To Acquire Blyth For $6/Share
Morning Market Gainers
Gilead's Next Logical Acquisition, Part 1: NASH And Galmed (Seeking Alpha)

On Monday, Bank of America released a bullish note on Intercept Pharmaceuticals (NASDAQ: ICPT). Shares trended higher throughout the session, spiking over the $440 level just minutes before the bell. The stock closed up nearly 8 percent.

Analyst Rachel McMinn believes the company should see FDA and EU regulators' support on using reversal of steatohepatitis, with no fibrosis progression, as surrogate histologic endpoint. Intercept's endpoint is to approve non-alcoholic steatohepatitis (NASH) drugs for the pre-cirrhotic population, according to the BofA analyst.

McMinn believes that regulators will need Phase 3 studies for approval, but regulators won't require CV outcomes data prior to approval.

Latest Ratings for ICPT

Aug 2015Morgan StanleyInitiates Coverage onUnderweight
May 2015BarclaysInitiates Coverage onOverweight
May 2015Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings


Related Articles (ICPT)

Get Benzinga's Newsletters